Impact of Liraglutide on Endothelial Function and Microvascular Blood Flow in Type 2 Diabetes Mellitus

NCT01208012 on ClinicalTrials.gov · last registry update 2011-03-15

Finished November 2010, after enrolling 44 people. Primary outcome, as filed: The difference in increase of retinal blood flow after flicker stimulation of retinal endothelial cells. liraglutide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.

Status: COMPLETED
Phase: P4
Drug: liraglutide
Saxenda, Victoza, Xultophy
Sponsor: ikfe-CRO GmbH
Sponsor type: Industry
Enrollment: 44
Started: 2010-04
Primary completion: 2010-11 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

The difference in increase of retinal blood flow after flicker stimulation of retinal endothelial cells

Conditions studied

Diabetes Mellitus, Type 2

Every field above is taken directly from the registry record. See all detected changes across the class, or the liraglutide page for this molecule’s full trial and approval history.